MD Anderson Cancer Center shared a post on LinkedIn:
“New research from MD Anderson shows that teclistamab, a bispecific antibody, is safe and effective for older patients with relapsed/refractory multiple myeloma. In a study led by our Dr. Oren Pasvolsky and Dr. Hans Lee, patients ages 75 and older experienced similar safety and better progression-free survival compared to younger patients. These findings may help expand access to this promising therapy for older adults.”
More posts featuring MD Anderson Cancer Center.